BRAF and melanoma: Vemurafenib significantly decreased the cell viability compared with the untreated control in melanoma cell lines with BRAF V600E mutant, and combined treatment with melatonin significantly enhanced the suppression of cell viability in a dose-dependent manner compared with the treatment with vemurafenib alone (Fig. 1a).